Cited by 1,324Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

Open access
Lorenzo, A, Yankner, B A·1994·Proceedings of the National Academy of Sciences

Abstract

beta-Amyloid (beta A) is normally produced as a nontoxic soluble peptide. In Alzheimer disease, beta A aggregates and accumulates in the brain as inert diffuse plaques or compact plaques associated with neurodegenerative changes. To determine the relationship of neurotoxicity to the physical state of beta A, we created (i) nonamyloidogenic amorphous aggregates of beta A [amorphous beta A (Am-beta A)] analogous to diffuse plaques and (ii) amyloidogenic fibrils of beta A [fibrillar beta A (Fib-beta A)] analogous to compact plaques. In primary rat hippocampal culture, Fib-beta A was neurotoxic, whereas Am-beta A was not toxic. Fib-beta A caused significant loss of synapses in viable neurons, while Am-beta A had no effect on synapse number. The amyloid fibril-binding dye Congo red inhibited Fib-beta A neurotoxicity by inhibiting fibril formation or by binding to preformed fibrils. Congo red also inhibited the pancreatic islet cell toxicity of diabetes-associated amylin, another type of amyloid fibril. These results indicate that beta A neurotoxicity requires fibril formation. These findings and our previous demonstration that amylin fibrils are toxic suggest that a common cytopathic effect of amyloid fibrils may contribute to the pathogenesis of Alzheimer disease and other amyloidoses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.91.25.12243

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effect of synthetic Aβ might depend on the concentration of amyloid, the incubation time, and the presence of fibrillar or oligomeric amyloid.

    “the effect of synthetic Aβ might depend on the concentration of amyloid, the incubation time, and the presence of fibrillar or oligomeric amyloid [41].”

    From Pharmacological ablation of astrocytes reduces Aβ degradation and synaptic connectivity in an ex vivo model of Alzheimer’s disease (2021) · cites this paper as [41]

    The Abstract reports that fibrillar Aβ was neurotoxic in primary rat hippocampal cultures, whereas amorphous Aβ was not, supporting a dependence on physical form. Our copy does not establish that the effect depends on amyloid concentration or incubation time, and it does not compare fibrils with oligomers. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Busciglio J., Gabuzda D. H., Matsudaira P., Yankner B. A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2092–2096. doi: 10.1073/pnas.90.5.2092. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  2. Busciglio J., Lorenzo A., Yankner B. A. Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol Aging. 1992 Sep-Oct;13(5):609–612. doi: 10.1016/0197-4580(92)90065-6. [DOI] [PubMed] [Google Scholar] · DOI
  3. Caughey B., Brown K., Raymond G. J., Katzenstein G. E., Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol. 1994 Apr;68(4):2135–2141. doi: 10.1128/jvi.68.4.2135-2141.1994. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  4. Caughey B., Ernst D., Race R. E. Congo red inhibition of scrapie agent replication. J Virol. 1993 Oct;67(10):6270–6272. doi: 10.1128/jvi.67.10.6270-6272.1993. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  5. Caughey B., Race R. E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem. 1992 Aug;59(2):768–771. doi: 10.1111/j.1471-4159.1992.tb09437.x. [DOI] [PubMed] [Google Scholar] · DOI
  6. Davies C. A., Mann D. M. Is the "preamyloid" of diffuse plaques in Alzheimer's disease really nonfibrillar? Am J Pathol. 1993 Dec;143(6):1594–1605. [PMC free article] [PubMed] [Google Scholar]
  7. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., Tagliavini F. Neurotoxicity of a prion protein fragment. Nature. 1993 Apr 8;362(6420):543–546. doi: 10.1038/362543a0. [DOI] [PubMed] [Google Scholar] · DOI
  8. Frautschy S. A., Baird A., Cole G. M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362–8366. doi: 10.1073/pnas.88.19.8362. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  9. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  10. Goldfarb L. G., Brown P., Haltia M., Ghiso J., Frangione B., Gajdusek D. C. Synthetic peptides corresponding to different mutated regions of the amyloid gene in familial Creutzfeldt-Jakob disease show enhanced in vitro formation of morphologically different amyloid fibrils. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4451–4454. doi: 10.1073/pnas.90.10.4451. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  11. Kowall N. W., Beal M. F., Busciglio J., Duffy L. K., Yankner B. A. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7247–7251. doi: 10.1073/pnas.88.16.7247. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  12. Lorenzo A., Razzaboni B., Weir G. C., Yankner B. A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994 Apr 21;368(6473):756–760. doi: 10.1038/368756a0. [DOI] [PubMed] [Google Scholar] · DOI
  13. Masters C. L., Multhaup G., Simms G., Pottgiesser J., Martins R. N., Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985 Nov;4(11):2757–2763. doi: 10.1002/j.1460-2075.1985.tb04000.x. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  14. Mattson M. P., Tomaselli K. J., Rydel R. E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 1993 Sep 3;621(1):35–49. doi: 10.1016/0006-8993(93)90295-x. [DOI] [PubMed] [Google Scholar] · DOI
  15. May P. C., Boggs L. N., Fuson K. S. Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity. J Neurochem. 1993 Dec;61(6):2330–2333. doi: 10.1111/j.1471-4159.1993.tb07480.x. [DOI] [PubMed] [Google Scholar] · DOI
  16. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., Cotman C. W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993 Apr;13(4):1676–1687. doi: 10.1523/JNEUROSCI.13-04-01676.1993. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  17. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991 Nov 1;563(1-2):311–314. doi: 10.1016/0006-8993(91)91553-d. [DOI] [PubMed] [Google Scholar] · DOI
  18. Roher A. E., Ball M. J., Bhave S. V., Wakade A. R. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun. 1991 Jan 31;174(2):572–579. doi: 10.1016/0006-291x(91)91455-l. [DOI] [PubMed] [Google Scholar] · DOI
  19. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zürcher-Neely H. A., Heinrikson R. L., Ball M. J. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993 Feb 15;268(5):3072–3083. [PubMed] [Google Scholar]
  20. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham E. F., Wright S., Lieberburg I., Becker G. W., Brems D. N. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994 Mar;45(3):373–379. [PubMed] [Google Scholar]
  21. Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 Oct;30(4):572–580. doi: 10.1002/ana.410300410. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  22. Verga L., Frangione B., Tagliavini F., Giaccone G., Migheli A., Bugiani O. Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett. 1989 Nov 6;105(3):294–299. doi: 10.1016/0304-3940(89)90636-8. [DOI] [PubMed] [Google Scholar] · DOI
  23. Yamaguchi H., Nakazato Y., Shoji M., Takatama M., Hirai S. Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropathol. 1991;82(1):13–20. doi: 10.1007/BF00310918. [DOI] [PubMed] [Google Scholar] · DOI
  24. Yankner B. A. Commentary and perspective on studies of beta amyloid neurotoxicity. Neurobiol Aging. 1992 Sep-Oct;13(5):615–616. doi: 10.1016/0197-4580(92)90067-8. [DOI] [PubMed] [Google Scholar] · DOI
  25. Yankner B. A., Duffy L. K., Kirschner D. A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990 Oct 12;250(4978):279–282. doi: 10.1126/science.2218531. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  26. Yankner B. A., Mesulam M. M. Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med. 1991 Dec 26;325(26):1849–1857. doi: 10.1056/NEJM199112263252605. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Lorenzo, A., & Yankner, B. A.
Affiliations
  • Harvard University (US)
  • Boston Children's Hospital (US)
Venue
Proceedings of the National Academy of Sciences
Published
1994-12-06
Volume
91
Issue
25
Pages
12243-12247
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1981570625
Cited by
1,324
References
5
Citations by year
2026: 7 · 2025: 9 · 2024: 17 · 2023: 22 · 2022: 15 · 2021: 20 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 34 · 2016: 28 · 2015: 36 · 2014: 40 · 2013: 34 · 2012: 43
FWCI
21.49
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • National Institutes of Health (5r29ag009229-05)
  • National Institute on Aging (AG09229)
  • National Institute of Neurological Disorders and Stroke (R01NS030352, NS30352)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, neurotoxicity, amyloid fibril formation, Congo red, Alzheimer's disease, synaptic loss, hippocampal neurons, amylin, amyloid plaques, amyloidosis
MeSH terms
Amyloid, Animals, Cells, Cultured, Congo Red, Dose-Response Relationship, Drug, Hippocampus, Islets of Langerhans, Nerve Degeneration, Neurons, Neurotoxins, Structure-Activity Relationship, Synapses, Amyloid beta-Peptides, Rats, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review